论文部分内容阅读
肥胖已成为一种世界范围内流行的慢性病,严重危害人类健康。目前,肥胖的治疗包括饮食、运动、用药和手术,其中饮食和运动疗法仍然是基础。然而,这些方法都不理想。寻找治疗肥胖的有效药物成为一种新的趋势。有研究表明,内源性大麻素系统在调节食欲、代谢和保持机体能量平衡方面发挥着重要作用,与肥胖的发生发展有着密切的联系。它使人们对肥胖有了更深一步的认识,也为肥胖的临床治疗提供了新的思路。大麻素CB1受体拮抗剂利莫那班在显示有效临床减肥作用的同时,还有明显的副作用,难以成为减肥新药。
Obesity has become a chronic disease that is prevalent in the world and seriously endangers human health. At present, obesity treatment includes diet, exercise, medication and surgery, of which diet and exercise therapy are still the foundation. However, these methods are not ideal. Finding effective drugs for the treatment of obesity has become a new trend. Studies have shown that the endocannabinoid system plays an important role in regulating appetite, metabolism and maintaining body energy balance, and is closely linked with the occurrence and development of obesity. It makes people have a deeper understanding of obesity, but also for the clinical treatment of obesity provides a new way of thinking. Cannabinoid CB1 receptor antagonist rimonabant showed effective clinical weight loss while there are obvious side effects, it is difficult to become a new drug to lose weight.